Clinical Trial Update: Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating neoadjuvant tislelizumab combined with nab-paclitaxel, followed by distal ureterectomy, for ureteral cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Ureter

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Status: RECRUITING